Drew Ranieri
Stock Analyst at Morgan Stanley
(1.25)
# 3,655
Out of 5,173 analysts
170
Total ratings
44.57%
Success rate
-11.85%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $12.99 | +77.06% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $87.21 | +14.67% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $12.15 | +72.84% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.47 | +143.41% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $332.59 | +33.80% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $9.43 | +186.32% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $1.26 | +534.92% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $14.80 | +48.65% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.38 | -40.21% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.62 | +2,182.16% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $25.82 | +47.17% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $58.46 | +64.21% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $13.40 | +94.03% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $156.23 | +88.82% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $105.85 | +164.53% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $9.00 | -44.44% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $16.61 | +321.43% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $478.04 | -37.24% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $12.99
Upside: +77.06%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $87.21
Upside: +14.67%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $12.15
Upside: +72.84%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.47
Upside: +143.41%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $332.59
Upside: +33.80%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $9.43
Upside: +186.32%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $1.26
Upside: +534.92%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $14.80
Upside: +48.65%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.38
Upside: -40.21%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.62
Upside: +2,182.16%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $25.82
Upside: +47.17%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $58.46
Upside: +64.21%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $13.40
Upside: +94.03%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $156.23
Upside: +88.82%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $105.85
Upside: +164.53%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $9.00
Upside: -44.44%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $16.61
Upside: +321.43%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $478.04
Upside: -37.24%